Innovative immunotherapy for pancreatic cancer using tumor-specific T cells


In this project, a method for the identification of tumor-specific cytotoxic T cells, without knowledge of the tumor antigens recognized by T cells, is being further developed for use in pancreatic cancer. In addition to tumor-specific cytotoxic T cells, helper T cells are also identified, produced by gene transfer and tested for tumor reactivity. To demonstrate the tumor reactivity of produced T cells, a microtumor model system is being developed at the NMI using pancreatic carcinoma tissue from patients at the University Hospital for General, Visceral and Transplantation Surgery in Tübingen. This will result in a novel combination of cellular immunotherapy and diagnostic efficacy testing for pancreatic cancer.

01.02.2020 - 31.07.2022